clinical trial · NCT06508762
A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993
Vertex Pharmaceuticals Incorporated·phase1·completed·n = 24
PainVX-993
brief summary
The purpose of the study is to evaluate the pharmacokinetics (PK), safety, and tolerability of VX-993 in healthy adult participants.
started
Jul 26, 2024
primary completion
Sep 10, 2024
completion
Sep 10, 2024
last updated
Oct 10, 2024
detailed description
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).
official title
A Phase 1, Open-label, Randomized, Crossover Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993 in Healthy Adult Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol